TNFRSF4 and neoplasm: Given the critical role for effector CD8 T cells in promoting tumor rejection following dual anti-OX40/IL-2c therapy (Fig. 6C), the lack of change in Treg function suggests that alteration of Treg suppression is not the major mechanism by which dual therapy promotes tumor rejection.